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Toward the Identiﬁcation of 
a Genetic Risk Signature for 
Pulmonary Aspergillosis in 
Chronic Obstructive Pulmonary 
Disease
To the Editor—In this issue of Clinical 
Infectious Diseases, He et  al. report on 
the association of genetic variants in 
the long pentraxin-3 (PTX3) and risk of 
pulmonary aspergillosis in chronic ob-
structive pulmonary disease (COPD) 
[1]. The management of COPD remains 
a formidable challenge as the result of the 
deteriorating lung function sustained by 
a nonresolving inflammatory response. 
The steroid therapy required to control 
inflammation is one major factor trig-
gering the onset of infectious complica-
tions. There is thus a pressing demand for 
innovative prognostic, diagnostic, and 
therapeutic interventions relevant to dis-
ease progression and its complications.
Genetic variation in PTX3 has already 
been recognized as a major determinant 
of susceptibility to aspergillosis in stem-
cell [2, 3] and solid organ transplant 
recipients [4, 5]. By validating these 
findings in COPD patients, He et  al. 
further highlight the potential applic-
ability of PTX3-based genetic markers 
in predicting infection across patients 
with intrinsically different predispos-
ing conditions and disease courses. 
Importantly, the evaluation of the prog-
nostic value of PTX3 variants to risk 
of infection in other interstitial lung 
diseases such as sarcoidosis, in which 
aspergillosis is also a serious complica-
tion [6], is warranted.
The clinical translation of these find-
ings to the setting of interstitial lung 
diseases is however precluded by the 
limited sample size of the study and 
the lack of independent validation. In 
addition, despite positive, the associ-
ation test results differ considerably 
from earlier reports. He et al. describe 
the association of the AA genotype at 
rs1840680 with aspergillosis in COPD 
[1], whereas we and others instead 
demonstrated a role for the GG geno-
type in stem-cell transplant recipients 
[2, 4, 7]. We reasoned that this could 
be due to the different genotype dis-
tributions across the individuals of 
European and Asian ancestry used in 
these studies or to population stratifi-
cation issues that the authors did not 
consider. Even so, it remains unclear 
why both genotypes impaired the levels 
of PTX3. Remarkably, common genetic 
variants are known to account for dif-
ferences in gene expression among 
ethnic groups [8]. In this regard, a 
transcription enhancer encompassing 
the second exon of PTX3 (including 
rs1840680) has recently emerged as 
a fine regulator of PTX3 expression 
during inflammation [9], whose activ-
ity could well depend on the genetic 
background. The course of infection 
is also typically different in transplant 
recipients and COPD patients, and this 
context specificity may likely impact 
regulation of gene expression and func-
tion. Whatever the mechanism(s) in 
place, several studies have now con-
firmed PTX3 as an indisputable genetic 
marker for risk of aspergillosis across 
different underlying conditions and 
ethnicities.
The study by He et  al. represents a 
first step toward uncovering the genetic 
susceptibility profile of COPD patients 
to aspergillosis. Recruitment of larger 
and carefully controlled cohorts of 
patients, as well as functional studies 
dissecting the PTX3-driven mecha-
nisms of association with infection, are 
ultimately required. This will undoubt-
edly support the integration of these 
genetic markers into clinically valid 
processes aimed at the stratification of 
risk and progression of fungal infection 
in COPD patients.
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Reply to Cunha and Carvalho
To the Editor—Cunha et al. suggest 
that a transcription enhancer can affect 
PTX3 expression during inflammation 
[1], which remind us whether there is a 
relationship between enhancers and sin-
gle-nucleotide polymorphisms (SNPs) in 
pulmonary aspergillosis. Enhancers are 
DNA sequences that can activate tran-
scription independent of their location, 
distance, or orientation [2]. Genetic var-
iance in enhancer sequences can alter 
transcription factor binding, changing the 
gene expression and finally the suscepti-
bility to diseases [3, 4]. Previous reports 
have been reported in breast cancer resist-
ance protein locus; SNPs can alter enhan-
cer activity in vitro and in vivo [5]. In 
another study of PTX3, enhancer2, which 
including the sequence of rs1840680, can 
affect the expression of PTX3 in mac-
rophage [6]. All of these suggest to us that 
there is a relationship between enhancers 
and SNPs. We agree with Cunha et al. 
that the different results between us may 
be due to the different disease entity and 
different races. In our study, the most 
common risk factor for aspergillosis in 
patients with chronic obstructive pul-
monary disease (COPD) is to be treated 
with glucocorticoids. It can affect airway 
inflammation through CCAAT/enhan-
cer binding proteins (CEBPs) [7]. CEBPs 
are transcription factors that can directly 
interact with the DNA [8]. Experiments 
are warranted to verify which enhanc-
ers may affect the transcription of PTX3 
expression in pulmonary aspergillosis. 
Meanwhile, we need to expand our study 
from COPD population to other disease 
entities in the future.
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Follow-up Blood Cultures: A 2.0 
Diagnostic Tool in Patients With 
Gram-Negative Bacteremia and 
Septic Thrombophlebitis
To the Editor—We read with great 
interest the study by Canzoneri et al on 
the value and usefulness of follow-up 
blood cultures (FUBCs) in the man-
agement of gram-negative bloodstream 
infections [1]. The authors found that 
FUBCs add little value in terms of de-
cision making and may not be indicated 
in this setting because of likely health-
care cost increases and longer hospital 
stays. We believe that a possible excep-
tion to the authors’ conclusions occurs 
in the management of septic thrombo-
phlebitis (ST). In fact, in critical care 
settings, thrombophlebitis can develop 
as a consequence of invasive procedures 
such as the implantation and use of an 
endovascular indwelling catheter. In the 
case of bacteremia, this might repre-
sent a suitable medium to sustain bac-
terial growth and subsequent persistent 
endovascular infection [2, 3]. In this re-
gard, we recently observed some cases 
of ST due to gram-negative infections 
with long-term positive blood cultures 
despite in vitro appropriate antibiotic 
therapy (Table  1). Notwithstanding 
the persistent bacteremia, the clinical 
course of these endovascular infections 
was indolent, with no multiple organ 
failure and fever and without raised 
procalcitonin. Indeed, the observation 
of definite clinical improvement despite 
persistently positive blood cultures was 
a crucial point that prompted further 
investigations to rule out endocarditis 
or ST.
Under these circumstances, long-term 
intravenous antibiotic treatment is 
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